骨形成不全症治療の世界市場レポート2025年

骨形成不全症治療の市場規模は、今後数年間で安定した成長が見込まれます。2029年の年間平均成長率（CAGR）は4.4%で、11億1,000万米ドルに成長すると予想されます。成長の促進要因としては、起立耐性失調症患者数の増加、遺伝性疾患に対する認識と診断率の向上、骨の健康をターゲットとした効率的な治療に対する需要の急増、希少疾患治療研究への資金提供の拡大、モノクローナル抗体開発における技術革新の進展などが予測されます。予測期間中に予想される主な動向には、モノクローナル抗体工学の進歩、3D骨診断・画像化技術の革新、先進ドラッグデリバリー機構のブレークスルー、幹細胞・再生治療ソリューションの進化、患者を遠隔管理する遠隔医療プラットフォームの採用拡大などがあります。

骨形成不全症の有病率の上昇が骨形成不全症治療市場の成長に大きく寄与しています。i型コラーゲンの欠陥や不足により骨がもろく折れやすいという特徴を持つこの遺伝子疾患は、遺伝子検査の改善や診断意識の高まりにより、より頻繁に発見されるようになっています。こうした進歩により、以前は診断されていなかった症例が発見されるようになっています。骨形成不全症の治療は、骨を丈夫にし、骨折のリスクを減らし、症状を管理し、患者の運動能力と全体的な生活の質を向上させることに重点を置いています。例えば、2022年6月、英国議会は、英国で約5,000人が骨形成不全症に罹患していると報告しました。このように、診断された症例数の増加が市場成長を促進する上で重要な役割を果たしています。

骨形成不全症治療市場の企業は、骨形成を促進し患者の骨折リスクを最小化するために、スクレロスチン阻害療法などの先進的治療薬にますます注力しています。このアプローチは、モノクローナル抗体を用いて骨の成長を阻害するタンパク質であるスクレロスチンを阻害し、骨密度と強度を高めるものです。例えば、2024年10月、米国のバイオ医薬品会社であるウルトラジェニックス・ファーマシューティカル社は、治験薬セトルズマブ（UX143）についてFDAから画期的治療薬指定を受けた。Setrusumabは完全ヒト型モノクローナル抗体で、スクレロスチンを阻害し、新生骨の成長を促し、骨強度を向上させ、2歳以上のi、III、IV型骨形成不全症患者の骨折リスクを軽減するよう設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の骨形成不全症治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の骨形成不全症治療市場：成長率分析
• 世界の骨形成不全症治療市場の実績：規模と成長, 2019-2024
• 世界の骨形成不全症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の骨形成不全症治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の骨形成不全症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 手術
• 理学療法
• ライフスタイルの変更
• 世界の骨形成不全症治療市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テリパラチド
• デノスマブ
• その他の薬物クラス
• 世界の骨形成不全症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 静脈内
• オーラル
• その他の投与経路
• 世界の骨形成不全症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の骨形成不全症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の骨形成不全症治療市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスホスホネート
• テリパラチド
• ホルモン補充療法
• 鎮痛剤
• カルシウムとビタミンDのサプリメント
• 世界の骨形成不全症治療市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロッディング手術
• 脊椎固定手術
• 骨折修復手術
• 関節置換手術
• 世界の骨形成不全症治療市場理学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 筋力トレーニング
• 可動域運動
• 水中療法
• 歩行訓練
• 補助器具トレーニング
• 世界の骨形成不全症治療市場ライフスタイルの変更の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養カウンセリング
• 転倒予防戦略
• 家庭環境の改造
• 活動の修正
• 患者教育およびサポートプログラム

第7章 地域別・国別分析

• 世界の骨形成不全症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨形成不全症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨形成不全症治療市場：競合情勢
• 骨形成不全症治療市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd
• Regeneron Pharmaceuticals Inc.
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.
• Aurobindo Pharma
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• BioMarin Pharmaceutical Inc.
• Stada Arzneimittel AG
• Alkem Laboratories Ltd.
• Ultragenyx Pharmaceutical Inc.
• OrthoPediatrics Corp.
• Ascendis Pharma A/S
• Pfenex Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨形成不全症治療市場2029：新たな機会を提供する国
• 骨形成不全症治療市場2029：新たな機会を提供するセグメント
• 骨形成不全症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Osteogenesis imperfecta treatment involves a comprehensive approach encompassing medical, surgical, and supportive care strategies to manage symptoms, enhance bone strength, minimize the risk of fractures, and improve the overall quality of life for individuals living with osteogenesis imperfecta (OI), a hereditary condition marked by fragile bones.

The primary treatment options for osteogenesis imperfecta include medication, surgery, physical therapy, and lifestyle changes. Medications involve the administration of pharmaceutical agents to treat or manage medical conditions. In the context of OI, drugs such as bisphosphonates, teriparatide, and monoclonal antibodies are utilized to fortify bones and lower the likelihood of fractures. These medications fall into categories such as teriparatide, denosumab, among others, and are administered through various routes, including subcutaneous, intravenous, and oral methods. Distribution occurs through hospital pharmacies, retail pharmacies, and online platforms, serving a range of end users like hospitals, homecare services, specialized clinics, and other medical facilities.

The osteogenesis imperfecta treatment market research report is one of a series of new reports from The Business Research Company that provides osteogenesis imperfecta treatment market statistics, including the osteogenesis imperfecta treatment industry's global market size, regional shares, competitors with the osteogenesis imperfecta treatment market share, detailed osteogenesis imperfecta treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteogenesis imperfecta treatment market. This osteogenesis imperfecta treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.89 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this historical growth include a rise in clinical trials focused on OI-specific medications, increased spending on rare disease healthcare, enhanced emphasis on personalized and regenerative treatments, broader access to genetic screening and counseling services, and strengthened partnerships between pharmaceutical and biotechnology firms.

The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Projected growth drivers include a rising number of OI cases, improved awareness and diagnostic rates of genetic conditions, surging demand for efficient therapies targeting bone health, expanded funding for research in rare disease treatment, and increased innovation in monoclonal antibody development. Key trends anticipated during the forecast period include progress in monoclonal antibody engineering, innovations in 3D bone diagnostic and imaging technologies, breakthroughs in advanced drug delivery mechanisms, evolving stem cell and regenerative treatment solutions, and greater adoption of telehealth platforms for managing patients remotely.

The rising prevalence of osteogenesis imperfecta is contributing significantly to the growth of the osteogenesis imperfecta treatment market. This genetic disorder, characterized by fragile bones that break easily due to defective or insufficient type I collagen, is being detected more frequently owing to improved genetic testing and heightened diagnostic awareness. These advancements have led to the identification of cases that were previously undiagnosed. Treatments for osteogenesis imperfecta focus on strengthening bones, reducing the risk of fractures, managing symptoms, and improving patients' mobility and overall quality of life. For example, in June 2022, the Parliament of the United Kingdom reported that approximately 5,000 people in the UK were affected by osteogenesis imperfecta. As such, the increasing number of diagnosed cases is playing a key role in driving market growth.

Companies in the osteogenesis imperfecta treatment market are increasingly focusing on advanced therapeutics, such as sclerostin inhibition therapy, to enhance bone formation and minimize the risk of fractures in patients. This approach uses monoclonal antibodies to block sclerostin, a protein that inhibits bone growth, thereby boosting bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company based in the United States, received Breakthrough Therapy Designation from the FDA for its investigational drug setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, encouraging new bone growth and improving bone strength to reduce the risk of fractures in patients with Types I, III, and IV of osteogenesis imperfecta aged two years and older.

In June 2022, Sirana Pharma GmbH, a biotechnology company based in Germany, entered into a collaboration with Pfizer Inc. to develop and validate new drug candidates aimed at the regenerative repair of muscle and bone tissue affected by osteogenesis imperfecta. This initiative utilizes Sirana's proprietary microRNA-targeting platform. Pfizer Inc., a US-based pharmaceutical firm, is known for its wide-ranging treatments in areas such as vaccines, oncology, internal medicine, and rare diseases.

Major players in the osteogenesis imperfecta treatment market are Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, and BioSenic SA.

North America was the largest region in the osteogenesis imperfecta treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteogenesis imperfecta treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteogenesis imperfecta treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteogenesis imperfecta treatment market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, and orthopedic support. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteogenesis imperfecta treatment market also includes sales of bisphosphonates, intramedullary rods, and braces and splints. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteogenesis Imperfecta Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteogenesis imperfecta treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteogenesis imperfecta treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteogenesis imperfecta treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medication; Surgery; Physical Therapy; Lifestyle Modifications
• 2) By Drug Class: Teriparatide; Denosumab; Other Drug Classes
• 3) By Route Of Administration: Subcutaneous; Intravenous; Oral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Bisphosphonates; Teriparatide; Hormone Replacement Therapy; Pain Relievers; Calcium And Vitamin D Supplements
• 2) By Surgery: Rodding Surgery; Spinal Fusion Surgery; Fracture Repair Surgery; Joint Replacement Surgery
• 3) By Physical Therapy: Strength Training; Range Of Motion Exercises; Aquatic Therapy; Gait Training; Assistive Device Training
• 4) By Lifestyle Modifications: Nutritional Counseling; Fall Prevention Strategies; Home Environment Modification; Activity Modification; Patient Education And Support Programs
• Companies Mentioned: Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteogenesis Imperfecta Treatment Market Characteristics

3. Osteogenesis Imperfecta Treatment Market Trends And Strategies

4. Osteogenesis Imperfecta Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Osteogenesis Imperfecta Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteogenesis Imperfecta Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteogenesis Imperfecta Treatment Market Growth Rate Analysis
• 5.4. Global Osteogenesis Imperfecta Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteogenesis Imperfecta Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteogenesis Imperfecta Treatment Total Addressable Market (TAM)

6. Osteogenesis Imperfecta Treatment Market Segmentation

• 6.1. Global Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Physical Therapy
• Lifestyle Modifications
• 6.2. Global Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teriparatide
• Denosumab
• Other Drug Classes
• 6.3. Global Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• Oral
• Other Routes Of Administration
• 6.4. Global Osteogenesis Imperfecta Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Osteogenesis Imperfecta Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Osteogenesis Imperfecta Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Teriparatide
• Hormone Replacement Therapy
• Pain Relievers
• Calcium And Vitamin D Supplements
• 6.7. Global Osteogenesis Imperfecta Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rodding Surgery
• Spinal Fusion Surgery
• Fracture Repair Surgery
• Joint Replacement Surgery
• 6.8. Global Osteogenesis Imperfecta Treatment Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Strength Training
• Range of Motion Exercises
• Aquatic Therapy
• Gait Training
• Assistive Device Training
• 6.9. Global Osteogenesis Imperfecta Treatment Market, Sub-Segmentation Of Lifestyle Modifications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Counseling
• Fall Prevention Strategies
• Home Environment Modification
• Activity Modification
• Patient Education And Support Programs

7. Osteogenesis Imperfecta Treatment Market Regional And Country Analysis

• 7.1. Global Osteogenesis Imperfecta Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteogenesis Imperfecta Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteogenesis Imperfecta Treatment Market

• 8.1. Asia-Pacific Osteogenesis Imperfecta Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteogenesis Imperfecta Treatment Market

• 9.1. China Osteogenesis Imperfecta Treatment Market Overview
• 9.2. China Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteogenesis Imperfecta Treatment Market

• 10.1. India Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteogenesis Imperfecta Treatment Market

• 11.1. Japan Osteogenesis Imperfecta Treatment Market Overview
• 11.2. Japan Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteogenesis Imperfecta Treatment Market

• 12.1. Australia Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteogenesis Imperfecta Treatment Market

• 13.1. Indonesia Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteogenesis Imperfecta Treatment Market

• 14.1. South Korea Osteogenesis Imperfecta Treatment Market Overview
• 14.2. South Korea Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteogenesis Imperfecta Treatment Market

• 15.1. Western Europe Osteogenesis Imperfecta Treatment Market Overview
• 15.2. Western Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteogenesis Imperfecta Treatment Market

• 16.1. UK Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteogenesis Imperfecta Treatment Market

• 17.1. Germany Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteogenesis Imperfecta Treatment Market

• 18.1. France Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteogenesis Imperfecta Treatment Market

• 19.1. Italy Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteogenesis Imperfecta Treatment Market

• 20.1. Spain Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteogenesis Imperfecta Treatment Market

• 21.1. Eastern Europe Osteogenesis Imperfecta Treatment Market Overview
• 21.2. Eastern Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteogenesis Imperfecta Treatment Market

• 22.1. Russia Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteogenesis Imperfecta Treatment Market

• 23.1. North America Osteogenesis Imperfecta Treatment Market Overview
• 23.2. North America Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteogenesis Imperfecta Treatment Market

• 24.1. USA Osteogenesis Imperfecta Treatment Market Overview
• 24.2. USA Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteogenesis Imperfecta Treatment Market

• 25.1. Canada Osteogenesis Imperfecta Treatment Market Overview
• 25.2. Canada Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteogenesis Imperfecta Treatment Market

• 26.1. South America Osteogenesis Imperfecta Treatment Market Overview
• 26.2. South America Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteogenesis Imperfecta Treatment Market

• 27.1. Brazil Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteogenesis Imperfecta Treatment Market

• 28.1. Middle East Osteogenesis Imperfecta Treatment Market Overview
• 28.2. Middle East Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteogenesis Imperfecta Treatment Market

• 29.1. Africa Osteogenesis Imperfecta Treatment Market Overview
• 29.2. Africa Osteogenesis Imperfecta Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteogenesis Imperfecta Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteogenesis Imperfecta Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteogenesis Imperfecta Treatment Market Competitive Landscape And Company Profiles

• 30.1. Osteogenesis Imperfecta Treatment Market Competitive Landscape
• 30.2. Osteogenesis Imperfecta Treatment Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Osteogenesis Imperfecta Treatment Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Fresenius Kabi AG
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Apotex Inc.
• 31.6. Aurobindo Pharma
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Cipla Ltd.
• 31.9. BioMarin Pharmaceutical Inc.
• 31.10. Stada Arzneimittel AG
• 31.11. Alkem Laboratories Ltd.
• 31.12. Ultragenyx Pharmaceutical Inc.
• 31.13. OrthoPediatrics Corp.
• 31.14. Ascendis Pharma A/S
• 31.15. Pfenex Inc.

32. Global Osteogenesis Imperfecta Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteogenesis Imperfecta Treatment Market

34. Recent Developments In The Osteogenesis Imperfecta Treatment Market

35. Osteogenesis Imperfecta Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Osteogenesis Imperfecta Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteogenesis Imperfecta Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteogenesis Imperfecta Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer